Safety, Immunogenicity and Immediate Pain of Intramuscular Versus Subcutaneous Administration of a Measles-mumps-rubella-varicella Vaccine to Children Aged 11-21 Months

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2010 Feb 12

PMID 20148263

Citations 16

Authors

Markus Knuf

Fred Zepp

Claudius U Meyer

Pirmin Habermehl

Lothar Maurer

Hanns-Michael Burow

Ulrich Behre

Michel Janssens

Paul Willems

Helmtrud Bisanz

Volker Vetter

Ruprecht Schmidt-Ott

Affiliations

Soon will be listed here.

Abstract

This study compared intramuscular and subcutaneous administration of two doses of measles-mumps-rubella-varicella (MMRV) combination vaccine (Priorix-Tetra, GlaxoSmithKline Biologicals) in children. Healthy children (N = 328) were randomised to receive MMRV either intramuscularly or subcutaneously. Reactogenicity was similar between treatment groups for immediate vaccination pain, vaccination site pain, redness and incidence of fever and rashes. Slightly less vaccination site swelling occurred during days 0-3 of the post-vaccination period after intramuscular administration. Seroconversion rates for all components, 42-56 days post-dose 2, ranged from 99.3% to 100% in the intramuscular group and from 98.6% to 100% in the subcutaneous. Cell-mediated immunity data supported the humoral immunogenicity findings. In summary, the MMRV vaccine is well tolerated and highly immunogenic when administered either subcutaneously or intramuscularly to children in the second year of life.

Citing Articles

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant.

Yang N, Garcia A, Meyer C, Tuschl T, Merghoub T, Wolchok J NPJ Vaccines. 2022; 7(1):120.

PMID: 36261460 PMC: 9580433. DOI: 10.1038/s41541-022-00542-5.

Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.

Bougouma E, Palacpac N, Tiono A, Nebie I, Ouedraogo A, Houard S Front Immunol. 2022; 13:978591.

PMID: 36119062 PMC: 9471861. DOI: 10.3389/fimmu.2022.978591.

In vivo fate and intracellular trafficking of vaccine delivery systems.

Lee J, Kim D, Byun J, Wu Y, Park J, Oh Y Adv Drug Deliv Rev. 2022; 186:114325.

PMID: 35550392 PMC: 9085465. DOI: 10.1016/j.addr.2022.114325.

Subcutaneous vaccine administration - an outmoded practice.

Cook I Hum Vaccin Immunother. 2020; 17(5):1329-1341.

PMID: 32991241 PMC: 8086591. DOI: 10.1080/21645515.2020.1814094.

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations.

Li Z, Chen Z, Cheng X, Wu X, Li G, Zhen Y Int J Immunopathol Pharmacol. 2020; 34:2058738420934618.

PMID: 32627611 PMC: 7338642. DOI: 10.1177/2058738420934618.

References

Marin M, Guris D, Chaves S, Schmid S, Seward J . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-4):1-40. View

Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P . Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006; 25(1):12-8. DOI: 10.1097/01.inf.0000195626.35239.58. View

Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K . Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008; 27(8):724-30. DOI: 10.1097/INF.0b013e318170bb22. View

Reisinger K, Brown M, Xu J, Sullivan B, Marshall G, Nauert B . A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics. 2006; 117(2):265-72. DOI: 10.1542/peds.2005-0092. View

Meyer P, Seward J, Jumaan A, Wharton M . Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000; 182(2):383-90. DOI: 10.1086/315714. View

Guillen J, Samaniego-Colmenero M, Hernandez-Barrera V, Gil A . Varicella paediatric hospitalizations in Spain. Epidemiol Infect. 2008; 137(4):519-25. DOI: 10.1017/S0950268808001131. View

Banz K, Wagenpfeil S, Neiss A, Hammerschmidt T, Wutzler P . The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ. 2004; 5(1):46-53. DOI: 10.1007/s10198-003-0200-7. View

Zepp F, Behre U, Kindler K, Laakmann K, Pankow-Culot H, Mannhardt-Laakmann W . Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate.... Eur J Pediatr. 2007; 166(8):857-64. DOI: 10.1007/s00431-007-0506-z. View

Ipp M, Cohen E, Goldbach M, Macarthur C . Pain response to M-M-R vaccination in 4-6 year old children. Can J Clin Pharmacol. 2006; 13(3):e296-9. View

10.

Clements C, Strassburg M, Cutts F, Torel C . The epidemiology of measles. World Health Stat Q. 1992; 45(2-3):285-91. View

11.

Gil A, San-Martin M, Carrasco P, Gonzalez A . Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004; 22(29-30):3947-51. DOI: 10.1016/j.vaccine.2004.04.004. View

12.

Gans H, Yasukawa L, Zhang C, Wakim R, Rinki M, DeHovitz R . Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. Viral Immunol. 2008; 21(2):163-72. PMC: 2599809. DOI: 10.1089/vim.2007.0113. View

13.

Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A . Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007; 26(7):632-8. DOI: 10.1097/INF.0b013e3180616c8f. View

14.

Nolan T, McIntyre P, Roberton D, Descamps D . Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine. 2002; 21(3-4):281-9. DOI: 10.1016/s0264-410x(02)00459-0. View

15.

Rentier B, Gershon A . Consensus: varicella vaccination of healthy children--a challenge for Europe. Pediatr Infect Dis J. 2004; 23(5):379-89. DOI: 10.1097/01.inf.0000122606.88429.8f. View

16.

Vesikari T, Baer M, Willems P . Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J. 2007; 26(2):153-8. DOI: 10.1097/01.inf.0000250689.09396.21. View

17.

Lanzavecchia A, Sallusto F . Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol. 2002; 2(12):982-7. DOI: 10.1038/nri959. View

18.

Hanna-Wakim R, Yasukawa L, Sung P, Arvin A, Gans H . Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis. 2008; 197(12):1669-75. PMC: 2561204. DOI: 10.1086/588195. View

19.

Ngai A, Staehle B, Kuter B, Cyanovich N, Cho I, Matthews H . Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J. 1996; 15(1):49-54. DOI: 10.1097/00006454-199601000-00011. View

20.

Goh P, Lim F, Han H, Willems P . Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection. 2007; 35(5):326-33. DOI: 10.1007/s15010-007-6337-z. View